Sodium - Sophion

Sodium channels

Sodium channels are highly selective for the transport of sodium ions across cell membranes.

 

Sodium channels are associated with a large range of channelopathies among others epilepsy, Dravet syndrome, West syndrome, Irritable bowel syndrome, long QT syndrome, neuropsychiatric disorders, pain and insensitivity to pain.

 

 

 

Multiple Na Channels

Posters

  • View Electrophysiological characterization of human dopaminergic neurons derived from LUHMES cells
    Year: 2019 First author: Kraushaar et Al.
  • View Biophysical and pharmacological profiling of multiple voltage-gated sodium channel subtypes on QPatch II
    Year: 2019 First author: Sauter et Al.
  • View Biophysical and pharmacological characterization of multiple Nav subtypes on Qube
    Year: 2016 First author: Lindqvist et Al
  • View Sophion analyzer as a tool for biophysical and pharmacological characterization of eight Nav subtypes evaluated in parallel on Qube
    Year: 2016 First author: Korsgaard et al., 2016
  • View Biophysical and pharmacological profiling of multiple Nav subtypes on QPatch HT
    Year: 2016 First author: Lindqvist et al., 2016

Reports

  • View Characterization of hiPSC-derived neurological disease models using automated patch clamp (Qube and QPatch)
    Year: 2019 First author: Rosholm et Al.

Nav1.1

Posters

  • View Adaptive voltage protocols increase precision of voltage-gated ion channel measurements on highthroughput automated patch clamp platforms
    Year: 2019 First author: Williams et Al, 2019
  • View Structure-based identification of novel KNa1.1 inhibitors
    Year: 2019 First author: Cole et Al., 2019
  • View Multi-parameter ion channel screening: mechanism-of-action data directly from HTS
    Year: 2019 First author: Kammonen et Al., 2019
  • View HT Automation for patch clamp based primary screen for Nav1.1 using Qube 384
    Year: 2018 First author: Klint et Al.

Papers

  • View The sodium channel activator Lu AE98134 normalizes the altered firing properties of fast spiking interneurons in Dlx5/6+/− mice
    Year: 2017 First author: von Schoubye et Al.
  • View A small molecule activator of Nav1.1 channels increases fast-spiking interneuron excitability and GABAergic transmission in vitro and has anti-convulsive effects in vivo
    Year: 2017 First author: K Frederiksen
  • View Using automated patch clamp electrophysiology platforms in pain-related ion channel research: insights from industry and academia
    Year: 2017 First author: Bell

Reports

  • View Nav1.1 currents on Qube
    Year: 2018 First author: Klint et Al.

Nav1.2

Posters

  • View Biophysical and pharmacological characterization of multiple Nav subtypes on Qube
    Year: 2016 First author: Lindqvist et Al
  • View Biophysical and pharmacological profiling of multiple Nav subtypes on QPatch HT
    Year: 2016 First author: Lindqvist et al., 2016
  • View Data quality is not affected by cell suspension density
    Year: 2006 First author: Mathes et al., 2006
  • View Exploring stem cell-derived cardiomyocytes with automated patch clamp techniques
    Year: 2012 First author: Schrøder et al., 2012
  • View Evaluation of throughput and data quality
    Year: 2009 First author: Olsen et al., 2009
  • View Pharmacological characterization of voltage- and ligand-gated ion channels
    Year: 2006 First author: Olsen et al., 2006

Papers

  • View Automated Patch Clamping Using the QPatch
    Year: 2009 First author: Jones et al. 2009
  • View Automated Planar Electrode Electrophysiology in Drug Discovery: Examples of the Use of QPatch in Basic Characterization and High Content Screening on Nav, KCa2.3, and Kv11.1 Channels
    Year: 2009 First author: Korsgaard et al., 2009
  • View QPatch: the missing link between HTS and ion channel drug discovery.
    Year: 2009 First author: Mathes
  • View Stable response for ligand and voltage-gated ion channels on QPatch
    Year: 2010 First author: Olsen et al., 2010
  • View 4-Substituted carbamazepine derivatives: conformational analysis and sodium channel-blocking properties
    Year: 2018 First author: Kanase et Al.
  • View Using automated patch clamp electrophysiology platforms in pain-related ion channel research: insights from industry and academia
    Year: 2017 First author: Bell

Reports

  • View Voltage-gated sodium channels on QPatch 16
    Year: 2012 First author: Olsen 2012

Nav1.3

Posters

  • View Biophysical and pharmacological profiling of multiple Nav subtypes on QPatch HT
    Year: 2016 First author: Lindqvist et al., 2016
  • View Biophysical and pharmacological characterization of multiple Nav subtypes on Qube
    Year: 2016 First author: Lindqvist et Al

Papers

  • View Using automated patch clamp electrophysiology platforms in pain-related ion channel research: insights from industry and academia
    Year: 2017 First author: Bell

Nav1.4

Posters

  • View Biophysical and pharmacological characterization of multiple Nav subtypes on Qube
    Year: 2016 First author: Lindqvist et Al
  • View Biophysical and pharmacological profiling of multiple Nav subtypes on QPatch HT
    Year: 2016 First author: Lindqvist et al., 2016
  • View RD(TE671)-nAChR a1 on QPatch
    Year: 2010 First author: Jensen et al., 2010

Papers

  • View Automated Planar Electrode Electrophysiology in Drug Discovery: Examples of the Use of QPatch in Basic Characterization and High Content Screening on Nav, KCa2.3, and Kv11.1 Channels
    Year: 2009 First author: Korsgaard et al., 2009
  • View The Snake with the Scorpion’s Sting: Novel Three-Finger Toxin Sodium Channel Activators from the Venom of the Long-Glanded Blue Coral Snake
    Year: 2016 First author: Yang et al., 2016
  • View Simultaneous assessment of compound activity on cardiac Nav1.5 peak and late currents in an automated patch clamp platform
    Year: 2019 First author: Guo et Al.

Reports

  • View High throughput screening for mode-of-action on Nav1.4
    Year: 2017 First author: Sauter

Nav1.5

Posters

  • View Functional Assessment of hNav1.x Ion Channels Using State- Dependent Protocols on the QPatch HT Automated Patch Clamp System
    Year: 2019 First author: Koci et Al.
  • View Verification of CiPA Recommended Voltage Protocols in Patch-Clamp Assay for hERG, Cav1.2 and Late Nav1.5 Currents
    Year: 2019 First author: Katayama et Al., 2019
  • View Biophysical and pharmacological characterization of multiple Nav subtypes on Qube
    Year: 2016 First author: Lindqvist et Al
  • View NaV1.5 big late : An inactivation deficient mutant of NaV1.5 as screening tool for late sodium currents of the cardiac action potential
    Year: 2018 First author: Bouyer et Al.
  • View Electrophysiological properties of iCell cardiomyocytes obtained by automated patch clamp
    Year: 2011 First author: Schrøder et al., 2011
  • View Qube as a tool for assay optimization of CiPA cells and protocols by using multiple IC, EC solutions and hERG, Nav1.5 and Cav1.2 on the same QChip
    Year: 2016 First author: Schupp et al., 2016
  • View Use- and state-dependent Nav1.5 blockers on QPatch X and in vivo and in vitro assays
    Year: 2010 First author: Jensen et al.
  • View Rapid generation of cells for ion channels assays: Efficient, large scale transfection using the MaxCyte STX
    Year: 2012 First author: Brady et al.
  • View Enhancing throughput with multiple cell lines per well
    Year: 2006 First author: Olsen et al.
  • View Nav1.5 use-dependent blockers on QPatch X
    Year: 2012 First author: Jacobsen et al., 2012
  • View Are stem-cell cardiomyocytes a viable cellular reagent for automated patch-clamp?
    Year: 2017 First author: Morton
  • View Simultaneous Measurement of Cardiac Nav1.5 Peak and Late Currents in an Automated QPatch Platform
    Year: 2018 First author: Guo et Al., 2018
  • View Simultaneous Measurement of Cardiac hERG and Nav1.5 Currents Using an Automated Qube® Patch Clamp Platform
    Year: 2018 First author: Guo et Al., 2018
  • View New CiPA cardiac ion channel cell lines and assays for in vitro proarrhythmia risk assessment
    Year: 2018 First author: Humphries et Al., 2018
  • View Hesperetin preferentially inhibits slow-activating currents of an LQT3 syndrome Na+ channel mutation
    Year: 2018 First author: Alvarez-Collazo et Al., 2018

Papers

  • View Eleclazine exhibits enhanced selectivity for long QT syndrome type 3–associated late Na+ current
    Year: 2017 First author: El-Bizri et Al.
  • View Use- and state-dependent Nav1.5 blockers on QPatch X and in vivo and in vitro assays
    Year: 2010 First author: Jensen et al.
  • View Automated Planar Electrode Electrophysiology in Drug Discovery: Examples of the Use of QPatch in Basic Characterization and High Content Screening on Nav, KCa2.3, and Kv11.1 Channels
    Year: 2009 First author: Korsgaard et al., 2009
  • View MICE Models: Superior to the HERG Model in Predicting Torsade de Pointes
    Year: 2013 First author: Kramer et al., 2013
  • View A new classifier-based strategy for in-silico ion-channel cardiac drug safety assessment
    Year: 2015 First author: Mistry et al., 2015
  • View Screening system for drug-induced arrhythmogenic risk combining a patch clamp and heart simulator
    Year: 2015 First author: Okada et al., 2015
  • View Using automated patch clamp electrophysiology platforms in pain-related ion channel research: insights from industry and academia
    Year: 2017 First author: Bell
  • View Cardiac sodium channel antagonism – Translation of preclinical in vitro assays to clinical QRS prolongation
    Year: 2017 First author: Jenkinson, S.
  • View Termination of Vernakalant-Resistant Atrial Fibrillation by Inhibition of Small-Conductance Ca2+-Activated K+ Channels in Pigs
    Year: 2017 First author: Diness, J Goldin et Al

Reports

  • View Nav1.5(Late) cardiac safety assay on QPatch
    Year: 2019 First author: Edward S A Humphries
  • View CHO-Nav1.5 on QPatch
    Year: 2012 First author: Olsen
  • View Use- and state-dependent Nav1.5 blockers on QPatch X and in vivo and in vitro assays
    Year: 2010 First author: Jensen et al.
  • View Cor.At cells embryonic stem cell derived cardiomyocytes on QPatch
    Year: 2009 First author: Schrøder et al., 2009
  • View Voltage-gated sodium channels on QPatch 16
    Year: 2012 First author: Olsen 2012

Nav1.6

Posters

  • View Biophysical and pharmacological characterization of multiple Nav subtypes on Qube
    Year: 2016 First author: Lindqvist et Al
  • View Biophysical and pharmacological profiling of multiple Nav subtypes on QPatch HT
    Year: 2016 First author: Lindqvist et al., 2016

Papers

  • View Direct evidence for high affinity blockade of NaV1.6 channel subtype by huwentoxin-IV spider peptide, using multiscale functional approaches
    Year: 2018 First author: Goncalves et Al.
  • View The E15R Point Mutation in Scorpion Toxin Cn2 Uncouples Its Depressant and Excitatory Activities on Human NaV1.6
    Year: 2018 First author: Israel et Al.

Nav1.7

Posters

  • View “Clip Detecting” with series resistance compensation using an automated patch clamp system
    Year: 2012 First author: Løjkner et al., 2012
  • View Biophysical and pharmacological characterization of multiple Nav subtypes on Qube
    Year: 2016 First author: Lindqvist et Al
  • View Biophysical and pharmacological profiling of multiple Nav subtypes on QPatch HT
    Year: 2016 First author: Lindqvist et al., 2016

Papers

  • View From identification to functional characterization of cyriotoxin-1a, an antinociceptive toxin from the spider Cyriopagopus schioedtei.
    Year: 2019 First author: Gonçalves et Al.
  • View Selective Nav1.7 Antagonists with Long Residence Time Show Improved Efficacy against Inflammatory and Neuropathic Pain
    Year: 2018 First author: Bankar et Al.
  • View Efficient Enzymatic Ligation of Inhibitor Cystine Knot Spider Venom Peptides: Using Sortase A To Form Double-Knottins That Probe Voltage-Gated Sodium Channel NaV1.7
    Year: 2018 First author: Agwa et Al
  • View Development of a high-throughput fluorescent no-wash sodium influx assay
    Year: 2019 First author: Tay et Al.
  • View Co-expression of β Subunits with the Voltage-Gated Sodium Channel NaV1.7: the Importance of Subunit Association and Phosphorylation and Their Effects on Channel Pharmacology and Biophysics
    Year: 2018 First author: Sokolov et Al.
  • View High-Throughput Screening of Nav1.7 Modulators Using a Giga-Seal Automated Patch Clamp Instrument
    Year: 2016 First author: Chambers et al., 2016
  • View Engineering Highly Potent and Selective Microproteins Against Nav1.7 Sodium Channel for Treatment of Pain
    Year: 2016 First author: Shcherbatko et al., 2016
  • View Structure- and Ligand-Based Discovery of Chromane Arylsulfonamide Nav1.7 Inhibitors for the Treatment of Chronic Pain
    Year: 2019 First author: McKerrall et Al.
  • View Rational engineering defines a molecular switch that is essential for activity of spider-venom peptides against the analgesics target Nav1.7
    Year: 2015 First author: Klint et al., 2015
  • View Using automated patch clamp electrophysiology platforms in pain-related ion channel research: insights from industry and academia
    Year: 2017 First author: Bell

Reports

  • View CHO-hNav1.7 assay on Qube pharmacology, biophysical characterization and the effect of internal fluoride
    Year: 2017 First author: Sauter et al., 2017

Nav1.8

Posters

  • View Biophysical and pharmacological characterization of multiple Nav subtypes on Qube
    Year: 2016 First author: Lindqvist et Al
  • View Biophysical and pharmacological profiling of multiple Nav subtypes on QPatch HT
    Year: 2016 First author: Lindqvist et al., 2016

Papers

  • View Using automated patch clamp electrophysiology platforms in pain-related ion channel research: insights from industry and academia
    Year: 2017 First author: Bell
Contact

This page is not optimized for smartphones and tablets.

Please visit on a larger screen.

Contact Sophion

Sophion Bioscience A/S
Baltorpvej 154, 2750 Ballerup, Denmark
Telephone: +45 44 60 88 00

You need to fill in all required fields.

When opting-in for our newsletter you will receive 4-6 newsletters per year. You can always opt-out directly from the newsletters. For more information see our privacy policy